NSE/BSE Codes: MAXHEALTH, 543220
Summary of Key Information
Nature of Event / Disclosure:
Regulatory disclosure under SEBI Listing Regulations (Regulation 30) regarding ongoing litigation proceedings before the National Company Law Tribunal (NCLT), Cuttack Bench.
Involved Parties / Authorities:
- Petitioner: Legal representatives of BRS Capital Two Pte. Limited
- Respondents: Kalinga Hospital Ltd. (subsidiary), Max Healthcare Institute Limited, and the other shareholder of KHL from whom the company acquired majority equity stake
- Adjudicating Authority: Hon'ble National Company Law Tribunal, Cuttack Bench
Date / Timeline of Event:
- Previous Intimation Date: August 19, 2026
- Hearing Date: September 8, 2026 at 3:00 PM (IST)
- Order Received Date: September 10, 2026 at 4:42 PM (IST)
- Next Hearing Date: September 28, 2026
- Filing Deadline: Respondents directed to file reply within one week from September 8, 2026
Brief Description of Outcome / Dispute:
The legal representatives of BRS Capital filed petitions including interlocutory petitions before the NCLT Cuttack Bench against Kalinga Hospital Ltd. (subsidiary), the company, and other shareholders. The petitions seek certain interim reliefs. The matter was heard on September 8, 2026.
Impact of Outcome:
Financial Impact:
No material financial impact disclosed at this stage. The disclosure explicitly states that settlement details, compensation/penalty paid, and financial impact are not applicable currently.
Operational / Business / Strategic Impact:
No material operational, business, or strategic impact disclosed in the current update. The matter remains sub-judice with interim relief petitions pending.
Other Implications:
The proceedings represent ongoing legal uncertainty regarding the company's subsidiary acquisition matters, requiring continued monitoring.
Next Steps / Required Actions:
- The company and other respondents must file their replies to the petitions within one week from September 8, 2026
- The next hearing is scheduled for September 28, 2026
- The company will continue to make disclosures as required under SEBI Listing Regulations